Stock Valuation Mastery: How to Determine What Any Company is Really Worth

Introduction: The $1 Million Question

"What is this stock really worth?" is the single most important question in investing. Get it right, and you buy dollars for pennies. Get it wrong, and you overpay for assets that destroy your wealth.

Warren Buffett's entire fortune (currently $120+ billion) comes from answering this question better than everyone else for 60 years. He didn't pick the fastest-growing companies or the hottest trends. He simply bought stocks trading below their intrinsic value and held until the market recognized their worth.

The Valuation Gap:

Professional Analysts:

• 40-60 hours building detailed valuation models
• DCF models, comparables analysis, scenario testing
• Proprietary data and research

Retail Investors:

• "The P/E is 15, seems cheap!"
• No fundamental analysis
• Buying/selling based on feelings

This guide bridges that gap, teaching you institutional-grade valuation methods you can apply yourself.

Core Concept: Intrinsic Value vs Market Price

Intrinsic Value: What a company is actually worth based on its fundamentals (cash flows, assets, growth, risk)

Market Price: What investors are currently paying for the stock

The Opportunity:

Markets are usually efficient, but occasionally:

• Intrinsic Value = $100
• Market Price = $60
• Margin of Safety: 40% ← BUY SIGNAL

Or:

• Intrinsic Value = $100
• Market Price = $150
• Overvalued by 50% ← AVOID/SELL

Benjamin Graham (Father of Value Investing):

"In the short run, the market is a voting machine. In the long run, it's a weighing machine."

Translation: Short-term prices = emotions. Long-term prices = fundamentals.

Your job: Calculate fundamentals, wait for market to catch up.

Method 1: Discounted Cash Flow (DCF) Analysis - The Gold Standard

The Concept:

A company's value equals all its future cash flows, discounted back to today's dollars.

Why It Works:

When you buy a stock, you're buying all future cash the business will generate. DCF calculates what those future cash flows are worth today.

The Formula:

Intrinsic Value = Σ (Future Cash Flows) / (1 + Discount Rate)^Year

Step-by-Step DCF Valuation:

Step 1: Project Free Cash Flows

Free Cash Flow (FCF) = Operating Cash Flow - Capital Expenditures

Example: Company ABC

Historical FCF:

• 2020: $500M
• 2021: $550M (+10%)
• 2022: $605M (+10%)
• 2023: $665M (+10%)
• 2024: $730M (+10%)

Growth Rate: 10% annually

Future Projections:

• 2025: $803M
• 2026: $883M
• 2027: $971M
• 2028: $1,068M
• 2029: $1,175M

Assumptions:

• Years 1-5: 10% growth (current trajectory)
• Years 6-10: 7% growth (maturation)
• Terminal growth: 3% (perpetuity)

Step 2: Determine Discount Rate (WACC)

Weighted Average Cost of Capital (WACC): The return investors require to invest in this company.

Simple WACC Calculation:

For Stable Blue Chip:

• Risk-free rate (10-year Treasury): 4.5%
• Equity risk premium: 5%
• Company beta: 1.0
• WACC = 4.5% + (1.0 × 5%) = 9.5%

For Growth Stock:

• Risk-free rate: 4.5%
• Equity risk premium: 5%
• Company beta: 1.5
• WACC = 4.5% + (1.5 × 5%) = 12%

For our Example (ABC):

• Beta: 1.2 (slightly volatile)
• WACC: 10.5%

Step 3: Discount Future Cash Flows to Present Value

Formula: Present Value = Future Cash Flow / (1 + WACC)^Year

Calculations:

Year 1 (2025): $803M / (1.105)^1 = $727M Year 2 (2026): $883M / (1.105)^2 = $723M Year 3 (2027): $971M / (1.105)^3 = $719M Year 4 (2028): $1,068M / (1.105)^4 = $716M Year 5 (2029): $1,175M / (1.105)^5 = $713M

Sum of Years 1-5 PV: $3,598M

Step 4: Calculate Terminal Value

Terminal Value = Final Year FCF × (1 + Perpetual Growth) / (WACC - Perpetual Growth)

Our Example:

• 2029 FCF: $1,175M
• Perpetual growth: 3%
• WACC: 10.5%

Terminal Value = $1,175M × 1.03 / (0.105 - 0.03) = $16,140M

Present Value of Terminal Value: $16,140M / (1.105)^5 = $9,793M

Step 5: Calculate Enterprise Value

Enterprise Value = PV of FCF (Years 1-5) + PV of Terminal Value

Our Example: $3,598M + $9,793M = $13,391M

Step 6: Calculate Equity Value

Equity Value = Enterprise Value - Net Debt + Cash

Company ABC Balance Sheet:

• Cash: $2,000M
• Debt: $3,500M
• Net Debt: $1,500M

Equity Value: $13,391M - $1,500M = $11,891M

Step 7: Calculate Value Per Share

Shares Outstanding: 500M shares

Intrinsic Value Per Share: $11,891M / 500M = $23.78

Current Market Price: $18.00

Margin of Safety: ($23.78 - $18.00) / $23.78 = 32% upside

Decision: BUY (trading at significant discount to intrinsic value)

Sensitivity Analysis (Critical!)

DCF models are sensitive to assumptions. Test different scenarios:

Base Case (Above): $23.78 Bull Case (12% growth, 9% WACC): $32.50 Bear Case (7% growth, 12% WACC): $16.20

Current Price: $18.00

Analysis:

• Even in bear case, stock fairly valued
• Base case: 32% upside
• Bull case: 81% upside
• Risk/reward favorable

Method 2: Relative Valuation (Comparables)

The Concept: Value a company relative to similar companies.

Most Common Multiples:

Price-to-Earnings (P/E) Ratio

Formula: P/E = Stock Price / Earnings Per Share

Example:

Company XYZ:

• Stock price: $50
• EPS: $3.00
• P/E: 16.7x

Comparable Companies:

• Competitor A: 18x P/E
• Competitor B: 19x P/E
• Competitor C: 17x P/E
• Industry Average: 18x

Valuation:

• XYZ P/E: 16.7x (below average)
• Fair value P/E: 18x
• Fair value price: $3.00 × 18 = $54
• Current price: $50
• Upside: 8% (modestly undervalued)

P/E Variations:

Trailing P/E: Uses last 12 months earnings (historical) Forward P/E: Uses next 12 months earnings (estimates)

Forward typically more relevant (you're buying future earnings)

Example:

• Stock at $100
• Trailing EPS: $4 (P/E = 25x, seems expensive)
• Forward EPS: $6 (P/E = 16.7x, actually reasonable)

Growth-Adjusted: PEG Ratio

PEG = P/E Ratio / Earnings Growth Rate

Example:

Company A:

• P/E: 30x
• Growth: 30%/year
• PEG: 1.0

Company B:

• P/E: 15x
• Growth: 5%/year
• PEG: 3.0

Interpretation:

• PEG < 1.0: Undervalued relative to growth
• PEG = 1.0: Fairly valued
• PEG > 2.0: Overvalued relative to growth

Company A (PEG 1.0) is better value despite higher P/E.

Price-to-Sales (P/S) Ratio

Useful for unprofitable companies or cyclical industries.

Formula: P/S = Market Cap / Annual Revenue

Example:

Tech Startup:

• Market cap: $500M
• Revenue: $100M
• P/S: 5x

Comparable Startups:

• Comp A: 7x P/S
• Comp B: 6x P/S
• Comp C: 8x P/S
• Average: 7x

Valuation:

• Fair value: $100M × 7x = $700M
• Current value: $500M
• Upside: 40%

Industry Benchmarks:

• SaaS companies: 5-15x sales
• Retailers: 0.5-2x sales
• Mature tech: 3-6x sales

Price-to-Book (P/B) Ratio

Useful for asset-heavy companies (banks, real estate, industrials).

Formula: P/B = Market Cap / Book Value (Shareholder Equity)

Example:

Bank Stock:

• Market cap: $20B
• Book value: $15B
• P/B: 1.33x

Comparable Banks:

• Bank A: 1.8x P/B
• Bank B: 1.6x P/B
• Bank C: 1.7x P/B
• Average: 1.7x

Valuation:

• Fair value: $15B × 1.7x = $25.5B
• Current value: $20B
• Upside: 27.5%

Interpretation:

• P/B < 1.0: Trading below liquidation value (deep value or troubled)
• P/B = 1.0-2.0: Reasonable for most companies
• P/B > 3.0: Premium valuation or asset-light business model

Enterprise Value to EBITDA (EV/EBITDA)

Most comprehensive multiple - accounts for debt, cash, and pre-tax earnings.

Formula: EV/EBITDA = (Market Cap + Debt - Cash) / EBITDA

Example:

Company DEF:

• Market cap: $10B
• Debt: $4B
• Cash: $1B
• Enterprise Value: $10B + $4B - $1B = $13B
• EBITDA: $2B
• EV/EBITDA: 6.5x

Comparables:

• Comp A: 8x
• Comp B: 7.5x
• Comp C: 8.5x
• Average: 8x

Implied Value:

• Fair EV: $2B × 8x = $16B
• Less net debt: $16B - $3B = $13B
• Current market cap: $10B
• Upside: 30%

Industry Benchmarks:

• High growth tech: 15-30x
• Stable industrials: 8-12x
• Mature companies: 6-10x
• Distressed: 4-6x

Method 3: Asset-Based Valuation

Best for: Real estate, holding companies, liquidation scenarios

Net Asset Value (NAV):

Formula: NAV = (Total Assets - Total Liabilities) / Shares Outstanding

Example: REIT Valuation

REIT Portfolio:

• 50 properties, fair value: $5B
• Cash: $200M
• Debt: $2B
• Shares outstanding: 100M

NAV Calculation: ($5B + $200M - $2B) / 100M = $32/share

Current Price: $28/share

Analysis:

• Trading at 12.5% discount to NAV
• Below liquidation value
• Potential value unlock

Sum-of-the-Parts (SOTP) Valuation:

For conglomerates with multiple business units.

Example: Berkshire Hathaway Style

Company XYZ Divisions:

Insurance Business:

• EBITDA: $3B
• Industry multiple: 10x
• Value: $30B

Railroad Business:

• EBITDA: $2B
• Industry multiple: 12x
• Value: $24B

Energy Business:

• EBITDA: $1B
• Industry multiple: 8x
• Value: $8B

Investment Portfolio:

• Market value: $50B

Total Value: $30B + $24B + $8B + $50B = $112B

Less Net Debt: -$15B

Equity Value: $97B

Shares Outstanding: 500M

Value Per Share: $194

Current Price: $150

Upside: 29% (conglomerate discount = opportunity)

Method 4: Dividend Discount Model (DDM)

Best for: Stable dividend-paying companies

The Gordon Growth Model:

Formula: Intrinsic Value = Next Year's Dividend / (Required Return - Dividend Growth Rate)

Example: Johnson & Johnson (JNJ)

Inputs:

• Current dividend: $4.76/share
• Dividend growth: 5% annually (60-year history)
• Next year dividend: $5.00
• Required return: 9%

Calculation: $5.00 / (0.09 - 0.05) = $5.00 / 0.04 = $125/share

Current Price: $150/share

Analysis: Overvalued by 20% (avoid or wait for pullback)

Multi-Stage DDM (More Realistic):

For companies with changing growth rates:

Stage 1 (Years 1-5): High growth (10%) Stage 2 (Years 6-10): Moderate growth (6%) Stage 3 (Forever): Terminal growth (3%)

Calculate each stage separately, discount all to present, sum them.

More accurate but complex - requires spreadsheet.

Real-World Valuation Example: Apple (AAPL)

Let's value Apple using multiple methods:

Method 1: DCF Analysis

Free Cash Flow (2024): $110B

Projections:

• 2025-2029: 8% annual growth
• 2030+: 4% terminal growth

WACC: 10% (slightly higher than market due to size)

DCF Calculation:

• PV of Years 1-5: $450B
• Terminal value: $3,200B
• PV of terminal: $2,000B
• Enterprise Value: $2,450B
• Less net debt: -$80B
• Equity Value: $2,370B

Shares Outstanding: 15.5B

DCF Value: $153/share

Method 2: P/E Comparable

Apple:

• EPS (forward): $7.00
• Current P/E: 26x

Comparables:

• Microsoft: 32x P/E
• Alphabet: 23x P/E
• Meta: 24x P/E
• Amazon: 48x P/E (outlier)
• Average (excl. Amazon): 26.3x

Fair Value: $7.00 × 26x = $182/share

Method 3: P/S Comparable

Apple:

• Revenue: $385B
• Market cap: $2,800B
• P/S: 7.3x

Big Tech Average: 6.5x P/S

Fair Value: $385B × 6.5x = $2,503B ($161/share)

Synthesis: Triangulating Value

DCF: $153/share P/E Comp: $182/share P/S Comp: $161/share

Average: $165/share

Current Price (example): $180/share

Conclusion: Slightly overvalued (8-9% above fair value)

Action: Hold if you own it, wait for pullback to $160-165 to buy more

Common Valuation Mistakes

1. Garbage In, Garbage Out

The Mistake: Using unrealistic growth assumptions

Example:

• Small company growing 50%/year
• Analyst assumes 50% growth for next 10 years
• DCF shows $1,000/share value

Reality:

• 50% growth compounds to 57x in 10 years
• $100M revenue company becomes $5.7B (unrealistic)
• 99% of companies can't maintain 50% for decade

The Fix:

• Conservative growth assumptions
• Declining growth over time (mean reversion)
• Sanity check final numbers

2. Ignoring Cyclicality

The Mistake: Valuing cyclical company at peak earnings

Example:

Oil Company at Peak:

• Oil at $120/barrel (peak)
• Earnings: $10/share
• P/E: 8x (looks cheap!)
• Buy at $80/share

Next Year:

• Oil crashes to $60/barrel
• Earnings: $2/share
• Stock: $30 (down 62%)

Problem: Used peak earnings (temporary) for valuation.

The Fix:

• Use normalized earnings (average through cycle)
• For oil company: Average earnings over 10 years
• Don't buy cyclicals at peak earnings multiples

3. Ignoring Capital Structure

The Mistake: Comparing companies without adjusting for debt

Example:

Company A:

• Market cap: $10B
• No debt
• Enterprise Value: $10B

Company B:

• Market cap: $10B
• Debt: $8B
• Enterprise Value: $18B

Both $10B market cap, but Company B is much more expensive (higher EV)

The Fix: Always use Enterprise Value for comparisons, not just market cap.

4. Using Multiples Without Context

The Mistake: "P/E is 10, must be cheap!"

Reality:

• Banks typically trade at 8-12x (asset-heavy, regulated)
• Tech typically trades at 20-40x (asset-light, growth)
• Comparing bank P/E to tech P/E = meaningless

The Fix:

• Compare to industry peers only
• Understand why multiples differ (growth, margins, returns on capital)

5. Forecast Precision Illusion

The Mistake: Building DCF model with 5 decimal places of precision

Reality:

• You're guessing cash flows 10 years out
• Small assumption changes = massive valuation swings
• False precision

The Fix:

• Value ranges, not single numbers
• "Stock worth $80-$120, currently $60" = buy
• Margin of safety accounts for uncertainty

Advanced Valuation Techniques

Economic Value Added (EVA)

Concept: Value created = Return on Capital - Cost of Capital

Formula: EVA = (ROIC - WACC) × Invested Capital

Example:

Company with:

• Invested capital: $10B
• ROIC: 15%
• WACC: 10%

EVA: (15% - 10%) × $10B = $500M/year value creation

Companies with positive EVA deserve premium valuations.

Microsoft:

• ROIC: 45%
• WACC: 10%
• EVA: 35% × capital = massive value creation
• Justifies high P/E multiple

Low-Margin Retailer:

• ROIC: 8%
• WACC: 10%
• EVA: Negative (destroying value)
• Deserves low/no valuation premium

Reverse DCF (Market Expectations)

Concept: Calculate what growth is implied by current price

Process:

1. Take current stock price as given
2. Work backwards to find growth rate
3. Ask: "Is this growth realistic?"

Example:

Stock at $200:

• Current FCF: $10/share
• WACC: 10%

Reverse DCF shows: Price implies 15% annual growth for 10 years

Question: Can this company grow 15%/year for decade?

• If yes: Fairly valued
• If no: Overvalued

Useful for stress-testing market optimism.

Real Options Valuation

For companies with future optionality (drug pipelines, exploration rights, patents)

Example: Biotech with Drug Pipeline

Current Business: $500M value (DCF of marketed drugs)

Pipeline Value:

• Drug A (Phase 3): 60% success probability × $2B potential = $1.2B
• Drug B (Phase 2): 30% probability × $5B potential = $1.5B
• Drug C (Phase 1): 10% probability × $3B potential = $300M

Total Pipeline Value: $3B

Total Company Value: $500M + $3B = $3.5B

Current Market Cap: $2B

Upside: 75% (market undervaluing pipeline)

Margin of Safety: The Benjamin Graham Principle

Concept: Only buy when price is significantly below intrinsic value to account for estimation errors.

The Math:

No Margin of Safety:

• Intrinsic value: $100
• Buy price: $100
• If wrong by 10%: Actual value $90, you lose 10%

With 30% Margin of Safety:

• Intrinsic value: $100
• Buy price: $70
• If wrong by 10%: Actual value $90, you still gain 29%

Margin of Safety Requirements:

Conservative Investors: 40-50% margin Moderate: 25-35% margin Aggressive: 15-20% margin

Never buy without at least 15% margin of safety.

Example:

Stock Analysis:

• DCF value: $120
• Comp value: $110
• Average: $115
• Margin required: 30%
• Max buy price: $115 × 0.70 = $80.50

Current price $85? Pass. Wait for $80 or below.

Practical Valuation Workflow

Weekly Stock Screening:

Step 1: Screen (5 minutes)

• P/E < 15
• P/B < 2
• Dividend yield > 2%
• Debt/Equity < 0.5

Generates: 50-100 candidates

Step 2: Quick Filter (30 minutes)

• Check business model (understandable?)
• Review recent news (any disasters?)
• Glance at 10-year financials (improving?)

Narrows to: 10-20 stocks

Step 3: Deep Dive (2-4 hours per stock)

• Build DCF model
• Comp analysis
• Read annual report
• Assess competitive position

Narrows to: 2-5 stocks

Step 4: Portfolio Decision (1 hour)

• Calculate position sizes
• Check correlation to existing holdings
• Determine buy prices
• Set price alerts

Result: 1-3 high-conviction buys

Conclusion: Valuation is an Art AND a Science

Valuation requires:

Science:

• Mathematical models (DCF, multiples)
• Financial data and ratios
• Comparable analysis

Art:

• Judgment about growth rates
• Competitive dynamics assessment
• Management quality evaluation
• Industry trends understanding

Your Valuation Toolkit:

Always Use:

1. DCF (intrinsic value)
2. P/E comparison (relative value)
3. Margin of safety (risk management)

Sometimes Use: 4. P/S (unprofitable companies) 5. P/B (asset-heavy businesses) 6. EV/EBITDA (comprehensive view)

Rarely Use: 7. Asset-based (special situations) 8. Real options (biotech, exploration)

Remember:

• All models are wrong, some are useful
• Value ranges, not precise numbers
• Margin of safety is mandatory
• When in doubt, pass
• Opportunities come regularly

The ultimate secret: It's better to be approximately right than precisely wrong. A rough valuation that identifies a 40% discount is more valuable than a precise model built on fantasy assumptions.

Value stocks properly, buy with a margin of safety, and let compounding do the work.

Ready to Analyze Your Next Investment?

Get a free AI-powered fair value analysis on any stock. See intrinsic value, margin of safety, and institutional-grade risk metrics in seconds. No credit card required.

Want full access to our institutional research tools? Explore Invest Daily Pro.